Related Experiment Videos
Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder
P T Joshi1, J A Capozzoli, J T Coyle
1Johns Hopkins Hospital, Baltimore, MD 21205.
Insights
Low-dose neuroleptics, such as haloperidol, show promise in treating childhood-onset pervasive developmental disorder. This treatment significantly reduced hyperactivity and aggression while improving peer relations in young patients with minimal side effects.
Area of Science:
- Child and Adolescent Psychiatry
- Neuropharmacology
- Developmental Disorders
Background:
- Childhood-onset pervasive developmental disorder (PDD) presents significant challenges in behavior and social interaction.
- Limited treatment options exist for PDD, necessitating exploration of novel therapeutic approaches.
Purpose of the Study:
- To evaluate the therapeutic efficacy of low-dose neuroleptic medication in children diagnosed with PDD.
- To assess the impact of low-dose haloperidol or fluphenazine hydrochloride on hyperactivity, aggression, and peer relations.
Main Methods:
- An open-label study was conducted on 12 hospitalized children (aged 7-11) meeting DSM-III criteria for PDD.
- Patients received an average daily dose of 0.04 mg/kg of haloperidol or fluphenazine hydrochloride.
- Behavioral symptoms and peer interactions were monitored throughout the treatment period.
Main Results:
- Significant reductions in hyperactivity and aggressive symptoms were observed in the patient group.
- Marked improvements in peer relations were noted following treatment.
- The low dosage of neuroleptics was associated with minimal adverse side effects.
Conclusions:
- Low-dose potent neuroleptics may represent an effective treatment strategy for select children with PDD.
- Further research is warranted to confirm these findings and establish optimal treatment protocols.
Abstract:
An open study of the therapeutic effects of low-dose neuroleptic treatment was performed on 12 consecutively hospitalized children, aged 7-11, who satisfied DSM-III criteria for childhood-onset pervasive developmental disorder. While receiving an average dose of 0.04 mg/kg per day of haloperidol or fluphenazine hydrochloride, the patients exhibited significant reductions in hyperactivity and aggressive symptoms and significant improvement in peer relations. This dose of neuroleptic was associated with minimal side effects. The authors conclude that low doses of potent neuroleptics may be effective treatment for some patients suffering from childhood-onset pervasive developmental disorder.